Clinical reference Biomarker Directory
Back to directory

APOA1

Emerging

APOA1 is the main HDL protein; low levels are linked to cardiovascular risk and, in research, worse cancer prognosis.

Also known as Apo A-I ApoA1
In plain language

APOA1 is the main protein in "good" HDL cholesterol. Beyond heart health, low levels have also been linked to worse outcomes in several types of cancer, an active area of ongoing research rather than routine testing.

Biomarker & context

Apolipoprotein A1 (APOA1) is the main protein component of HDL cholesterol, involved in reverse cholesterol transport from tissues back to the liver.

What it indicates

Low serum or tumor APOA1 has been associated with worse prognosis across several cancers (breast, gastric, pancreatic, hepatocellular), in addition to its established role as a marker of cardiovascular risk when HDL function is impaired.

Diagnosis & clinical testing

Measured via serum immunoassay as part of research-oriented lipoprotein panels; in oncology contexts, APOA1 is typically assessed as a research/prognostic marker rather than a standardized diagnostic test.

Guiding treatment

APOA1-mimetic peptides are in early preclinical development as a potential anti-tumor approach, exploiting APOA1's cholesterol-efflux properties to disrupt cancer cell membrane cholesterol homeostasis, though this remains investigational, not clinical practice.

Clinical significance

An active but still largely investigational research marker in oncology prognosis, beyond its established cardiovascular role.

References
  1. General lipidology and oncology reference literature on APOA1 in cardiovascular risk and cancer prognosis research.